REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Clinical trials for REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) trials appear
Sign up with your email to follow new studies for REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immunotherapy combo shows promise for stubborn lymphoma
Disease control OngoingThis phase 2 trial tests a combination of the immunotherapy drug glofitamab plus two chemotherapy drugs (gemcitabine and oxaliplatin) in 40 adults with refractory diffuse large B-cell lymphoma that did not respond to initial treatment. The main goal is to see how many patients ac…
Matched conditions: REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
Could a higher stem cell dose beat back lymphoma?
Disease control OngoingThis study looks at whether giving more stem cells during an autologous transplant helps people with relapsed or refractory diffuse large B-cell lymphoma recover better and stay cancer-free longer. About 59 adults who have already tried one chemotherapy will get high-dose chemo (…
Matched conditions: REFRACTORY DIFFUSE LARGE B CELL LYMPHOMA (DLBCL)
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC